dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Wang, Yifan |
dc.contributor.author | Bernhardy, Andrea J. |
dc.contributor.author | Nacson, Joseph |
dc.contributor.author | Krais, John J. |
dc.contributor.author | Tan, Yin-Fei |
dc.contributor.author | Nicolas, Emmanuelle |
dc.contributor.author | Llop Guevara, Alba |
dc.contributor.author | Balmaña Gelpí, Judith |
dc.contributor.author | Serra Elizalde, Violeta |
dc.date.accessioned | 2021-04-13T14:01:07Z |
dc.date.available | 2021-04-13T14:01:07Z |
dc.date.issued | 2019-12-11 |
dc.identifier.citation | Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, et al. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nat Commun. 2019 Dec 1;10(1):5661. |
dc.identifier.issn | 2041-1723 |
dc.identifier.uri | https://hdl.handle.net/11351/5845 |
dc.description | Resistència terapèutica contra el càncer; Càncer d'ovaris |
dc.description.sponsorship | This work was supported by the US National Institutes of Health (NIH) Grants P50 CA083638 and 5P30 CA006927, as well as R01CA214799, Susan Komen CCRCR17499048, and OC130212 Department of Defense to N.J., and a Pilot Award and Nested Teal Postdoctoral Scholar supported Y.W. (OC140040). We thank Drs. Judith Balmaña, Cristina Saura and Joaquin Arribas for providing materials. PDXs were established thanks to the GHD-Pink program, the FERO Foundation and the Catalan Agency AGAUR [2017 SGR 540]. V.S. is supported by the Instituto de Salud Carlos III (CP14/00228) and ALG by a PERIS fellowship from the Departament de Salut, Generalitat de Catalunya (SLT002/16/00477). Clovis Oncology supplied rucaparib. We are grateful to FCCC Genomics, Cell Culture and Cell Sorting facilities. We thank Hsin Yao Tang at the Wistar Proteomics facility for help with mass spectrometry. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Nature Communications;10(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Ovaris - Càncer |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Ovarian Neoplasms |
dc.subject.mesh | Drug Resistance, Neoplasm |
dc.title | BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41467-019-13530-6 |
dc.subject.decs | neoplasias ováricas |
dc.subject.decs | resistencia a los antineoplásicos |
dc.relation.publishversion | https://www.nature.com/articles/s41467-019-13530-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Wang Y, Bernhardy AJ, Krais JJ] Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. [Nacson J] Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19111, USA. [Tan YF] Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. [Nicolas E] Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Balmaña J] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 31827092 |
dc.identifier.wos | 000502101600001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CP14%2F00228 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR540 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/SLT002%2F16%2F00477 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |